We have a diversified and balanced clinical development pipeline, covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

The pipeline comprises 12 compounds, including 6 in late-stage development. The development of an innovative compound into a future therapy is a complex undertaking, which inevitably involves an element of risk. With our scientific, data-driven approach helping to mitigate risk at each step, we aim to bring at least three products to the market in the medium term.

We will take a simple, efficient approach to preparing product launches, utilizing shared, best in class platforms and ways of working that enable fast decision-making and cost-effective growth. We will focus on transforming treatment in underserved markets, such as insomnia, and building new markets, such as cerebral vasospasm, using scientific and medical evidence to engage effectively with experts in the field and with payors. We plan to remain flexible and nimble in the way we commercialize our portfolio, building the core capabilities required to successfully launch our products, while also being prepared to enter into partnerships where we need support to reach a primary care market.

We have established commercial operations in the US and Japan, with experienced leadership teams and strategic locations. We have also established a robust and lean global supply chain function to ensure consistent supplies of our innovative medicines to patients.

We believe that we have the potential to generate significant revenues from product sales, once the first of our development compounds has received regulatory approval.

To maximize the medical value of our discoveries and to provide a source of liquidity in the short to medium term, we have entered into several collaborative partnerships with pharmaceutical companies. These include development, commercialization and revenue-sharing agreements, under which we are eligible to receive milestone payments based on the progress of the development compound in question.

In addition to several drug candidates in the early stages of clinical and preclinical development, we must continue with our discovery efforts, to maintain a steady supply of innovative compounds to our pipeline. We aim to create a pipeline with a sales potential of at least CHF 5 billion.

Achieving this is dependent on a company-wide effort, so we must attract, retain and develop a talented and engaged workforce. We want our employees to feel proud of their work, and of the company they work for.

We integrate computational tools and digital technologies at various stages of the drug discovery, development and commercialization process, so as to maximize our potential and bring breakthrough medicines to patients.

We look for creative ways to harness advances in technology to focus on novel targets and use new drug development methods. All functions of the drug discovery, clinical and pharmaceutical development processes are streamlined to assist in the delivery of tailored, high-quality medicines.